HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Up-regulation of glyoxalase 1 by mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats.

Abstract
Advanced glycation endproducts (AGEs) and its precursor methylglyoxal are associated with diabetic nephropathy (DN). Mangiferin has many beneficial biological activities, including anti-inflammatory, anti-oxidative and anti-diabetic effects. We investigated the effect of mangiferin on DN and its potential mechanism associated with glyoxalase 1 (Glo-1), a detoxifying enzyme of methylglyoxal, in streptozotocin-induced rat model of DN. Diabetic rats were treated orally with mangiferin (15, 30, and 60 mg/kg) or distilled water for 9 weeks. Kidney tissues were collected for morphologic observation and the determination of associated biochemical parameters. The cultured mesangial cells were used to measure the activity of Glo-1 in vitro. Chronic treatment with mangiferin significantly ameliorated renal dysfunction in diabetic rats, as evidenced by decreases in albuminuria, blood urea nitrogen, kidney weight index, periodic acid-schiff stain positive mesangial matrix area, glomerular extracellular matrix expansion and accumulation, and glomerular basement membrane thickness. Meanwhile, mangiferin treatment caused substantial increases in the enzymatic activity of Glo-1 in vivo and in vitro, and protein and mRNA expression of Glo-1, reduced levels of AGEs and the protein and mRNA expression of their receptor (RAGE) in the renal cortex of diabetic rats. Moreover, mangiferin significantly attenuated oxidative stress damage as reflected by the lowered malondialdehyde and the increased glutathione levels in the kidney of diabetic rats. However, mangiferin did not affect the blood glucose and body weight of diabetic rats. Therefore, mangiferin can remarkably ameliorate DN in rats through inhibiting the AGEs/RAGE aix and oxidative stress damage, and Glo-1 may be a target for mangiferin action.
AuthorsYao-Wu Liu, Xia Zhu, Liang Zhang, Qian Lu, Jian-Yun Wang, Fan Zhang, Hao Guo, Jia-Le Yin, Xiao-Xing Yin
JournalEuropean journal of pharmacology (Eur J Pharmacol) Vol. 721 Issue 1-3 Pg. 355-64 (Dec 05 2013) ISSN: 1879-0712 [Electronic] Netherlands
PMID24036348 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 Elsevier B.V. All rights reserved.
Chemical References
  • Blood Glucose
  • Glycation End Products, Advanced
  • RNA, Messenger
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic
  • Xanthones
  • mangiferin
  • Lactoylglutathione Lyase
Topics
  • Animals
  • Blood Glucose (metabolism)
  • Body Weight (drug effects)
  • Diabetes Mellitus, Experimental (complications)
  • Diabetic Nephropathies (blood, genetics, metabolism, prevention & control)
  • Disease Progression
  • Fasting (blood)
  • Glycation End Products, Advanced (metabolism)
  • Lactoylglutathione Lyase (genetics)
  • Male
  • Oxidative Stress (drug effects)
  • RNA, Messenger (genetics, metabolism)
  • Rats
  • Rats, Sprague-Dawley
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic (genetics, metabolism)
  • Up-Regulation (drug effects)
  • Xanthones (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: